Inhibition of prothrombin activation by bothrojaracin, a C-type lectin from Bothrops jararaca venom.
Bothrojaracin is a potent and specific alpha-thrombin inhibitor (Kd approximately 0.6 nM) isolated from Bothrops jararaca venom. It binds to both of thrombin's anion-binding exosites (1 and 2), thus inhibiting the ability of the enzyme to act upon several natural macromolecular substrates, such as fibrinogen, platelet receptor, protein C, and factor V. Additionally, bothrojaracin interacts with prothrombin (Kd approximately 30 nM), as previously determined by a solid-phase assay. However, there is no information concerning the effect of this interaction on prothrombin activation and whether the binding of bothrojaracin can occur in plasma. Here, we show that bothrojaracin specifically interacts with prothrombin in human plasma. It is an effective anticoagulant after activation of the intrinsic pathway of blood coagulation, and analysis of prothrombin conversion in plasma shows that bothrojaracin strongly reduces alpha-thrombin formation. To determine whether this effect is due exclusively to inhibition of feedback reactions involving the thrombin-induced activation of factors V and VIII, we analyzed the effect of bothrojaracin on the activation of purified prothrombin by Oxyuranus scutellatus venom. As with plasma, bothrojaracin greatly inhibited thrombin formation, suggesting a direct interference in the prothrombin activation by the enzyme found in this venom (scuterin, a prothrombin activator described as a factor Xa/factor Va-like complex). Altogether, we suggest that bothrojaracin exerts its anticoagulant effect in plasma by two distinct mechanisms: (1) it binds generated thrombin and inhibits exosite 1 dependent activities such as fibrinogen clotting and factor V activation, and (2) it interacts with prothrombin and decreases its proteolytic activation. Thus, bothrojaracin may be useful in the search for thrombin inhibitors that bind both the zymogen and the active enzyme.
Monteiro
R Q
RQ
Departamento de Bioquímica Médica, ICB/CCS/UFRJ, Rio de Janeiro, Brazil.
Zingali
R B
RB
D000818:Animals; D000838:Anions; D000925:Anticoagulants / Q000494:pharmacology; D001665:Binding Sites; D015153:Blotting, Western; D017837:Bothrops; D003435:Crotalid Venoms / Q000737:chemistry* / Q000494:pharmacology*; D004546:Elapid Venoms / Q000737:chemistry; D004591:Electrophoresis, Polyacrylamide Gel; D004789:Enzyme Activation; D005165:Factor V / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D037102:Lectins / Q000494:pharmacology*; D010949:Plasma / Q000378:metabolism; D011485:Protein Binding; D011516:Prothrombin / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D013917:Thrombin / Q000096:biosynthesis; D013997:Time Factors
D000838:Anions; D000925:Anticoagulants; D003435:Crotalid Venoms; D004546:Elapid Venoms; D037102:Lectins; C083739:bothrojaracin; D005165:Factor V; D011516:Prothrombin; D005340:Fibrinogen; D013917:Thrombin